{"podcast":{"title":"Mesa News Today | 2 Min News | The Daily News Now!","slug":"mesa-news-today-2-min-news-the-daily-news-now-7559357","podcast_index_feed_id":7559357,"rss_url":"https://feeds.fastcast.ai/the-mesa-daily-news-now.xml","website_url":"https://thednn.ai/","image_url":"https://image.fastcast.ai/podcasts/the-mesa-daily-news-now.jpg","author":"The Daily News Now!","episode_count":901,"summary":"Hosted by Corey with the Story, Mesa News Today delivers fast, focused daily updates on the stories shaping Mesa—from local news and business to culture, sports, and community developments. Designed for quick, on-the-go listening, each episode brings you up to speed in minutes. Produced by AI for speed, consistency, and global scale, the show is part of The Daily News Now network—bringing local news to every city in the world and keeping communities connected. Mesa News Today is your daily snapshot of what’s happening in your city. Advertise on DNN: advertise@thednn.ai","last_synced_at":"2026-07-24T14:18:43.264316+00:00","page_url":"https://stenobird.com/podcast/mesa-news-today-2-min-news-the-daily-news-now-7559357"},"episode":{"title":"FDA Peptide Review Sparks Legal Battle | Mesa News","slug":"fda-peptide-review-sparks-legal-battle-mesa-news","published_at":"2026-07-10T19:54:42+00:00","page_url":"https://stenobird.com/podcast/mesa-news-today-2-min-news-the-daily-news-now-7559357/fda-peptide-review-sparks-legal-battle-mesa-news","show_page_url":"https://stenobird.com/podcast/mesa-news-today-2-min-news-the-daily-news-now-7559357","url":"https://sources.thednn.ai/604be4f17467593f","audio_url":"https://api.fastcast.ai/audio/fd923594-763b-4d2c-9d03-93558f13de8e.mp3","summary":"The FDA is poised to ban popular compounded peptides—key players in longevity and wellness—sparking a high-stakes legal battle with EVEXIAS Life Sciences, who’s suing over what they call unjustified restrictions. These short amino acid chains, used for healing, sleep, and inflammation, are trending as alternatives to traditional medicine, but the FDA argues they lack proper safety oversight. Meanwhile, experts warn against risky online purchases, urging patients to seek regulated sources. The outcome could redefine the future of peptide-based treatments—balancing innovation with safety. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/604be4f17467593f","meta_description":"The FDA is poised to ban popular compounded peptides—key players in longevity and wellness—sparking a high-stakes legal battle with EVEXIAS Life Sciences,…","key_points":[],"chapters":[],"topics":[],"duration_seconds":110,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/mesa-news-today-2-min-news-the-daily-news-now-7559357/episodes/fda-peptide-review-sparks-legal-battle-mesa-news/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/mesa-news-today-2-min-news-the-daily-news-now-7559357/fda-peptide-review-sparks-legal-battle-mesa-news.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}